Navigation Links
So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market

Hoffmann-La Roche Inc. CEO George Abercrombie, Pfizer R&D Head Martin Mackay, HHS Deputy Secretary Tevi Troy, Former CMS Administrator & FDA Commissioner Mark McClellan Headline Agenda at FDA/CMS Summit 2007

WASHINGTON, Nov. 15 /PRNewswire-USNewswire/ -- It's shaping up to be a record year for drug approvals. Unfortunately for the biopharma sector and investors, it's a record low. The Food and Drug Administration is on track to grant marketing approval to 18 or fewer new drugs in 2007, and pipelines are not looking better in the coming years. For the research and development and marketing executives responsible for getting new drugs to customers, the level of unpredictability may be unprecedented. And Washington lawmakers and regulators are driving the uncertainty. Yesterday's blockbuster will not be the prototype for future drug development. Sweeping new legislation is reforming the FDA and changing how drugs are developed; Medicare is radically altering product economics; and Wall Street is looking for the next big thing.

(Logo: )

The FDA/CMS Summit, taking place December 6-7 in Washington, D.C., will feature the key decision makers from government and industry to help biopharmaceutical executives understand what regulatory and policy developments mean for research and commercial success.

"Today may look a lot like yesterday, but the rules of the game have fundamentally changed," said Cole Werble, editor-in-chief of The RPM Report, the lead sponsor of the conference. "Industry needs to learn what recent changes to FDA law mean and what the impact might hold for drug development and marketing. The FDA/CMS Summit provides leaders in industry key insight from policy-makers who have been involved in these changes."

The FDA/CMS Summit provides health care executives with an exclusive oppo

SOURCE Windhover Information Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
9. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
(Date:10/9/2015)... and ROCKVILLE, Md. , ... a privately-held biotechnology company developing next generation vaccines ... it has entered into an exclusive worldwide licensing ... for the treatment or prevention of any and ... the agreement, Immunomic Therapeutics will receive an upfront ...
(Date:10/9/2015)... ... October 09, 2015 , ... From blood to food ... those cells from their surroundings for research, diagnostics, and cell therapy—also known as ... this, Ann Arbor-based startup Akadeum Life Sciences is developing a radically ...
(Date:10/8/2015)... Oct. 8, 2015   Intrexon Corporation (NYSE: ... announced the appointment of Joseph L. Vaillancourt ... Nir Nimrodi who continues in his role ... Intrexon,s endeavors to generate sustainable, biologically based solutions to ... where he held a variety of key roles including, ...
(Date:10/8/2015)...  ATCC, the premier global biological materials resource and ... by The Michael J. Fox Foundation for Parkinson,s Research ... and biotechnology organizations committed to speed a cure for ... , and more than 5 million worldwide, have ... , and more than 5 million worldwide, have ...
Breaking Biology Technology:
... VICL ) today announced the enhancement of ... de Guttadauro as Vice President, Corporate,Development. Prior ... Director of,Strategy at Biogen Idec since February 2007, ... that company,s Zevalin,the first radioimmunotherapy product approved for ...
... Mulia Pangkuan Negeri -, TORONTO, Aug. 20 ... on developing simple blood-based biomarker tests for the,early ... that its co-founder and Chief Scientific Officer, Dr. ... Negeri (DMPN), a State Honour,given by the Governor ...
... Poised for Market Launch, KIRKLAND, Wash., Aug. 20 ... for the treatment of arterial,disease, today announced that it ... has started building its sales team in preparation for ... Recently Pathway moved from its old 10,000-square-foot facility ...
Cached Biology Technology:
(Date:9/28/2015)... Sept. 28, 2015 CLEAR, the ... its expedited traveler service is coming to ... travel, bringing a frictionless experience, serious speed ... "CLEAR offers our travelers an expedited ... said Jim Smith , Executive Director, ...
(Date:9/26/2015)... , Sept. 26th, 2015  Results of ... will be unveiled today at the Stanford Medicine ... Engagement Using iPad Dashboards, Connected Health Devices and ... of Pharmacy 3.0, will explain how senior patients ... data to their pharmacist via the TactioRPM remote ...
(Date:9/10/2015)... 10, 2015 Report Details The ... delivered upon previous expectations of revenues, consumer adoption and ... year in which wearables begin to achieve that mass ... the main reasons is the entrance of Apple to ... SmartWatches market, but the overall size of the wearable ...
Breaking Biology News(10 mins):
... LA JOLLA, Calif., September 25 2013 A new ... called medulloblastoma has been developed by researchers at Sanford-Burnham ... cellsthe cells that are critical for maintaining tumor growthand ... are essential for tumor progression. The process destroys the ...
... how their meat is sourced, with animal welfare ... many purchases. Unfortunately, many widely-used livestock production methods ... from the University of Cambridge has identified what ... silvopastoral systems which include shrubs and trees with ...
... , Sept. 25, 2013   GenoVive , an innovator ... against the emerging "globesity" epidemic through its development of ... on each individual,s unique metabolism.  "Weight Loss Designed by ... to customize an all natural meal and exercise program ...
Cached Biology News: